ADA/EASD guidelines: Where do the SIGNs send us? Are the messages NICE?

Following the publication of the ADA/EASD guidelines for the Management of Hyperglycaemia in Type 2 Diabetes at EASD in 2018, Dr Seidu explores how these guidelines should impact the management of diabetes in the UK? Do the guidelines support the recommendations from SIGN and what update is needed from NICE?

Learning outcomes:

  • A chance to see the newly published ADA/EASD guidelines
  • How and why the guidelines were developed
  • Recommendations on what should change in the UK as a result of these guidelines
  • What is needed from NICE?

This session has been organised by Napp Pharma

Thursday 15th November 2018

10:05 - 10:35

Primary, Community & Specialist Care


Head of Research, Primary Care Diabetes Europe and primary care research fellow in diabetes at the University of Leicester, Hockley Farm Medical Practice, University of Leicester, Leicester Diabetes Centre

Our site is intended for UK Healthcare Professionals

Are you a UK Healthcare Professional?

We’re sending you to our partner charity’s site. 

DRWF provide information and support for people with diabetes and their friends & families